English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Molecular testing has been shown to improve turnaround time (TAT) for identifying bloodborne pathogens. Early results can inform directed escalation or de-escalation of antimicrobial therapy. Paired with antibiotic stewardship, rapid pathogen identification has been shown to reduce antibiotic utilization and improve patient outcomes. However, many of these studies were in single site institutions. We evaluated implementation of the BioFireÒ FilmArray Blood Culture Identification System (BCID) across 3 acute care facilities utilizing a central testing laboratory at Carolinas Healthcare. Methods BCID testing was implemented over a 2-month period. A multidisciplinary team developed standard protocols for processing, transport and testing, with communication of results across teams of stewardship pharmacists. Standard algorithms were used across all facilities to guide antibiotic prescribing. Data were collected between January and May 2017 from three sources (BacTec, Theradoc and Cerner EMR). Positive bottles were tracked from the time of the positive bottle alert through pharmacist intervention. We evaluate rates of interventions and consistency using variance comparison tests. Results 708 positive blood cultures were identified at 3 acute care facilities and tested using BCID. TAT from positive bottle to BCID result was 4.6 (95% CI 4.4–4.8) hours. 86.7% (614/708) were on appropriate empiric antimicrobials at the time of the BCID result. 28.0% (198/708) required a recommendation by a pharmacist. 39.6% (78/197) had an escalation recommendation while 26.4% (52/197) had a de-escalation recommendation. There was no significant variation across shifts or sites except with de-escalation where variation was greater than 10% across sites (P = 0.02). Conclusion BCID testing was successfully implemented across a large integrated healthcare system using central testing laboratory paired with a team of stewardship and virtual care pharmacists. Our strategy provided timely and reproducible results across facilities and shifts. Implementation of BCID allowed for more pathogen directed therapy at all facilities with variability in need for escalation and de-escalation of therapy between facilities. Disclosures All authors: No reported disclosures.

Successful Implementation of BCID Across Large Healthcare System Using a Central Testing Laboratory and Multidisciplinary Pharmacy Team